首页膀胱肿瘤治疗及预后证据详情

Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis

原文: 2019 年 发布于 Urolithiasis 10 卷 第 42 期 916-925 浏览量:162次

作者: Garcia-Perdomo H. A. Usubillaga-Velasquez J. P. Zapata-Copete J. A. Reis L. O.

作者单位: Department of Complex Genetics, Nutrition and Translational Research in Metabolism (School NUTRIM), Maastricht University, PO Box 616, 6200MD Maastricht, The Netherlands. f.vanosch@maastrichtuniversity.nl. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. f.vanosch@maastrichtuniversity.nl. Department of Complex Genetics, Nutrition and Translational Research in Metabolism (School NUTRIM), Maastricht University, PO Box 616, 6200MD Maastricht, The Netherlands. s.jochems@maastrichtuniversity.nl. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. s.jochems@maastrichtuniversity.nl. Department of Complex Genetics, Nutrition and Translational Research in Metabolism (School NUTRIM), Maastricht University, PO Box 616, 6200MD Maastricht, The Netherlands. anke.wesselius@maastrichtuniversity.nl. Department of Pharmacology and Toxicology, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, 6200MD Maastricht, The Netherlands. f.vanschooten@maastrichtuniversity.nl. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. r.t.bryan@bham.ac.uk. Department of Complex Genetics, Nutrition and Translational Research in Metabolism (School NUTRIM), Maastricht University, PO Box 616, 6200MD Maastricht, The Netherlands. m.zeegers@maastrichtuniversity.nl. Department of Complex Genetics, Public Health and Primary Care (School CAPHRI), Maastricht University, 6200MD Maastricht, The Netherlands. m.zeegers@maastrichtuniversity.nl.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1007/s11255-020-02406-0

关键词: Cd147 bladder cancer clinicopathological features meta-analysis prognosis

文献简介

Background: Various studies had explored the relationship between TP53 codon 72 polymorphisms and the risk of bladder cancer (BC). However, their results remained inconsistent and the definite role of smoking or tumor status associated with this polymorphism in BC cases was seldom involved. Hence, this meta-analysis was to disclose such associations. Methods: Systematical and comprehensive retrieval of online databases PubMed, PMC, EMBASE and Web of Science were conducted to obtain eligible studies, up to May 30th, 2018. Pooled odds ratios (ORs) with 95% confidence intervals (CI) were utilized to assess the associations between TP53 codon 72 polymorphisms and BC susceptibilities under five genetic comparison models. Results: Ultimately, this meta-analysis enrolled 22 applicable studies with 3,791 BC cases and 4,917 controls. Our results suggested that the variant genotypes were associated with BC risk in Asian subgroup (allele model: OR=1.19, 95% CI=1.04-1.34; dominant model: OR=1.27, 95% CI=1.06-1.52; homozygote model: OR=1.36, 95% CI=1.03-1.80), while negative outcomes were presented in Caucasians. In the relationship between TP53 codon 72 polymorphisms and BC tumor stage in Asian group, positive results were presented in allele model: OR=1.68, 95% CI=1.04-2.72; dominant model: OR=2.46, 95% CI=1.08-5.61; heterozygous model: OR=2.32, 95% CI=1.04-5.14; homozygote model: OR=2.66, 95% CI=1.04-6.81. However, no evidence was revealed between this polymorphism and BC tumor grade. Besides, significant associations were displayed between TP53 codon 72 polymorphism and smoking status (allele model: OR=1.40, 95% CI=1.06-1.84; dominant model OR=1.72, 95% CI=1.18-2.50; heterozygous model: OR=1.77, 95% CI=1.19-2.64). Conclusion: Taken together, our results shed light on that TP53 codon 72 polymorphism was significantly associated with the susceptibility to BC in Asians. In addition, positive associations were also revealed between this polymorphism and tumor stage/smoking status in BC cases.

热门文献